Armata Pharmaceuticals Inc (ARMP) Stock Price, Quote & News

Company Profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 665 2928

Fax: 310 665 2963

Website: www.armatapharma.com

Address:

5005 McConnell Avenue, Los Angeles, United States

History101 Feb. 23 at 10:10 PM

$IBRX my IBRX finished 5th and my $ARMP finished 8th on the WSJ leader board today!! awesome...

0 · Reply

TinyTiger19 Feb. 23 at 5:38 PM

.@SqueezeSharkie moving different. Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $BTG $KBSX $ARMP $FSM ~

0 · Reply

TinyTiger19 Feb. 23 at 4:21 PM

$VELO $TDW $ARMP $AUGO <<<>

0 · Reply

BioTuesdays Feb. 23 at 2:44 PM

$ARMP has announced that the FDA has granted AP-SA02 Qualified Infectious Disease Product (QIDP) designation for intravenous use in the adjunct treatment of complicated bacteremia caused by methicillin-sensitive S. aureus or methicillin resistant S. aureus. https://biotuesdays.com/2026/02/23/fda-grants-qidp-for-armatas-ap-sa02/

0 · Reply

OpenOutcrier Feb. 23 at 1:25 PM

$ARMP (+2.6% pre) FDA grants special status to phage therapy for dangerous staph infections https://ooc.bz/l/94221

0 · Reply

SystematicTrading Feb. 20 at 1:25 PM

$ARMP Armata Pharmaceuticals develops bacteriophage therapies. Clinical validation is key. Early-stage risk remains high.

1 · Reply

All_City_Baby Feb. 20 at 2:54 AM

$ARMP Get your popcorn ready!

0 · Reply

Trapped Feb. 20 at 2:27 AM

$ARMP $10 coming

0 · Reply

Trapped Feb. 20 at 2:26 AM

$ARMP and up we go!!!!

0 · Reply

EquityNest Feb. 18 at 6:51 AM

$ARMP Armata Pharmaceuticals develops phage therapies for antibiotic-resistant infections, facing novel regulatory pathways and clinical validation hurdles [citation:historical].

0 · Reply

Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02

Jan 13, 2026, 7:00 AM EST - 5 weeks ago

Armata Pharmaceuticals Announces End-of-Phase 2 Meeting with FDA and Plans to Advance AP-SA02 to a Phase 3 Superiority Study in Complicated BacteremiaStaphylococcusaureus

Nov 18, 2025, 7:00 AM EST - 3 months ago

Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST

Nov 12, 2025, 4:05 PM EST - 3 months ago

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Nov 10, 2025, 7:00 AM EST - 3 months ago

Armata Pharmaceuticals Announces Formal Commissioning of State-of-the-Art cGMP Phage Manufacturing Facility in Los Angeles, California

Oct 22, 2025, 11:10 AM EDT - 4 months ago

Armata Pharmaceuticals Highlights Positive Results from Phase 2a diSArm Study of its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, in Late-Breaking Oral Presentation at IDWeek 2025™

Oct 14, 2025, 7:00 AM EDT - 4 months ago

Armata Pharmaceuticals to Present Late-Breaking Clinical Data highlighting its Staphylococcus aureus Bacteriophage Cocktail, AP-SA02, at IDWeek 2025™

Sep 8, 2025, 7:00 AM EDT - 6 months ago

Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology

Sep 4, 2025, 7:00 AM EDT - 6 months ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 12, 2025, 4:05 PM EDT - 6 months ago

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

May 19, 2025, 7:00 AM EDT - 10 months ago

Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia

May 14, 2025, 4:05 PM EDT - 10 months ago

Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update

May 1, 2025, 7:00 AM EDT - 10 months ago

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Mar 20, 2025, 5:56 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Mar 12, 2025, 5:08 PM EDT - 1 year ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

INVA

Mar 11, 2025, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit

Dec 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 19, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting

Nov 13, 2024, 4:05 PM EST - 1 year ago

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update

Nov 12, 2024, 7:00 AM EST - 1 year ago

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Structural Biology Publication

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 7:30 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at the 2024 Military Health System Research Symposium

Aug 15, 2024, 4:45 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Second Quarter 2024 Results and Provides Corporate Update

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Receives $5.25 Million of Additional Non-Dilutive Grant Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Armata Pharmaceuticals Announces Completion of Enrollment of Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Jul 10, 2024, 4:05 PM EDT - 1 year ago

Armata Pharmaceuticals Announces Presentation at Viruses of Microbes 2024

May 7, 2024, 4:01 PM EDT - 1 year ago

Armata Pharmaceuticals Announces First Quarter 2024 Results and Provides Corporate Update

Mar 21, 2024, 4:05 PM EDT - 2 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

INVA

Feb 21, 2024, 7:00 AM EST - 2 years ago

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

Nov 14, 2023, 4:00 PM EST - 2 years ago

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Oct 19, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Aug 14, 2023, 7:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

May 31, 2023, 8:00 AM EDT - 2 years ago

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

May 11, 2023, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

Mar 16, 2023, 4:10 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

Mar 6, 2023, 6:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

Jan 10, 2023, 4:05 PM EST - 3 years ago

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

INVA

Dec 22, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

Nov 28, 2022, 8:00 AM EST - 3 years ago

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

Nov 9, 2022, 4:15 PM EST - 3 years ago

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

Aug 11, 2022, 4:05 PM EDT - 3 years ago

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

May 23, 2022, 8:00 AM EDT - 4 years ago

Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia due to Staphylococcus aureus

May 12, 2022, 4:17 PM EDT - 4 years ago

Armata Pharmaceuticals Announces First Quarter 2022 Results and Provides Corporate Update

History101 Feb. 23 at 10:10 PM

$IBRX my IBRX finished 5th and my $ARMP finished 8th on the WSJ leader board today!! awesome...

0 · Reply

TinyTiger19 Feb. 23 at 5:38 PM

.@SqueezeSharkie moving different. Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $BTG $KBSX $ARMP $FSM ~

0 · Reply

TinyTiger19 Feb. 23 at 4:21 PM

$VELO $TDW $ARMP $AUGO <<<>

0 · Reply

BioTuesdays Feb. 23 at 2:44 PM

0 · Reply

OpenOutcrier Feb. 23 at 1:25 PM

$ARMP (+2.6% pre) FDA grants special status to phage therapy for dangerous staph infections https://ooc.bz/l/94221

0 · Reply

SystematicTrading Feb. 20 at 1:25 PM

$ARMP Armata Pharmaceuticals develops bacteriophage therapies. Clinical validation is key. Early-stage risk remains high.

1 · Reply

All_City_Baby Feb. 20 at 2:54 AM

$ARMP Get your popcorn ready!

0 · Reply

Trapped Feb. 20 at 2:27 AM

$ARMP $10 coming

0 · Reply

Trapped Feb. 20 at 2:26 AM

$ARMP and up we go!!!!

0 · Reply

EquityNest Feb. 18 at 6:51 AM

$ARMP Armata Pharmaceuticals develops phage therapies for antibiotic-resistant infections, facing novel regulatory pathways and clinical validation hurdles [citation:historical].

0 · Reply

SuperGreenToday Feb. 17 at 9:45 PM

$ARMP Share Price: $8.15 Contract Selected: May 15, 2026 $10 Calls Buy Zone: $0.23 – $0.28 Target Zone: $0.37 – $0.45 Potential Upside: 51% ROI Time to Expiration: 86 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

BounceHeat Feb. 17 at 4:22 PM

$ARMP Armata Pharmaceuticals develops phage therapies for antibiotic-resistant infections, facing novel regulatory pathways and clinical validation hurdles [citation:historical].

0 · Reply

Trapped Feb. 11 at 11:52 PM

$ARMP going to 15. easily.

0 · Reply

All_City_Baby Feb. 11 at 9:13 PM

$ARMP Strong close at EOD.

0 · Reply

JavierLindemann471 Feb. 11 at 2:39 PM

$ARMP Armata Pharmaceuticals; clinical-stage biotech (phage therapy); novel approach, high scientific risk; manufacturing and regulatory pathways are unproven.

1 · Reply

Trapped Feb. 4 at 10:41 PM

$ARMP it’s so funny how this board is so quiet while the stock is up 400% for $2 my entry. i’m here till $50.

1 · Reply

NVDAMillionaire Feb. 4 at 5:04 PM

$ARMP Outstanding article that hits the mark on ARMP's current state. So if you want to refresh your ARMP insights or learn about ARMP from scratch, this is a must read. https://everyticker.com/quote/ARMP/analysis/armata-pharmaceuticals-phage-power-clinical-progress-and-the-race-for-capital-armp

1 · Reply

Trapped Feb. 3 at 11:03 AM

$ARMP hmmm past 7 already. looks like heading to 15 again before phase 3 concludes. could there be a buyer in the wings ??? p

1 · Reply

Trapped Feb. 2 at 10:37 PM

$ARMP a lot more coming. phase 3 going on with FDA do execute in LA office. going to be a good drug once it’s approved. just gotta wait. mean time value will continue to head north. buy and hold.

0 · Reply

History101 Feb. 2 at 9:02 PM

$ARMP damn, closed today with a 15% gain, glad i added earlier today. Anyone know why the big gain today?

0 · Reply

Trapped Feb. 2 at 6:39 PM

$ARMP i think we see $50 by end of this year.

0 · Reply

History101 Feb. 2 at 5:55 PM

$ARMP $7!!

0 · Reply

Market Cap	317.83M
Revenue (ttm)	5.17M
Net Income (ttm)	-18.92M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-365.96%
Debt to Equity Ratio	-1.53

Volume	132,199
Avg Vol	44,540
Day's Range	N/A - N/A
Shares Out	36.41M
Stochastic %K	100%
Beta	1.42
Analysts	Strong Sell
Price Target	$12.00